Compare FRSX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 2.0B |
| IPO Year | 2017 | 1997 |
| Metric | FRSX | VCEL |
|---|---|---|
| Price | $1.40 | $35.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | ★ 626.8K | 578.6K |
| Earning Date | 03-24-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | $452,000.00 | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $144.40 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $1.26 | $29.24 |
| 52 Week High | $12.60 | $63.00 |
| Indicator | FRSX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 39.93 |
| Support Level | $1.26 | $35.53 |
| Resistance Level | $1.74 | $38.15 |
| Average True Range (ATR) | 0.11 | 1.26 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 25.00 | 19.64 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.